ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MLND Millendo Therapeutics Inc

1.06
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Millendo Therapeutics Inc NASDAQ:MLND NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.06 1.06 1.07 0 01:00:00

Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

05/08/2020 1:30pm

Business Wire


Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Millendo Therapeutics Charts.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 12:35 p.m. EDT.

A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

Millendo Investor Contact: Connie Chang Millendo Therapeutics 734-864-8006 chang@millendo.com

Millendo Media Contact: Julie Bane MacDougall 617-821-1089 jbane@macbiocom.com

1 Year Millendo Therapeutics Chart

1 Year Millendo Therapeutics Chart

1 Month Millendo Therapeutics Chart

1 Month Millendo Therapeutics Chart

Your Recent History

Delayed Upgrade Clock